The Stupp protocol has become standard of care for the treatment of glioblastoma (GBM) (since its publication in 2005) and has led to some limited survival improvements. This protocol, consists of radiotherapy and concomitant chemotherapy with temozolomide, an alkylating agent. Temozolomide + radiation, compared to radiation alone had added in average 3 months additional life span, 16 percent improved survival at 2 years. That said since 2005, the standard of care has not changed in regards to the treatment of early diagnosed aggressive or multifocal GBM, and unfortunately the expected survival is still poor with 75 percent of patients dying in less than 2 years and average survival of 15 months. In patients with multifocal tumors (such as the case below) the average survival is even worse with less than 4 months at her age [1] . Here we present a case study of a patient with advanced multifocal, and rapidly progressing Glioblastoma Multiforme treated with STUPP protocol in combination with IV Quercetin. The patient experienced improved quality of life and response, compared to historical data. It is our recommendation to investigate such combinational approach in patients with Glioblastoma, as in our case it proved to be safe and effective with improved quality of life and performance as well as clinical response and survival.
 Radiotherapy  total 60 Gy  2 Gy per daily fraction (Monday to Friday) over 6 weeks  Temozolomide  during radiotherapy: 75 mg per square meter of body-surface area per day, 7 days per week  post-radiotherapy (adjuvant): six cycles consisting of 150 -200 mg per square meter for 5 days during each 28-day cycle Here are characteristic features of multifocal disease, which accounts for about 13 percent of cases:  In one retrospective study [2] , researchers reviewed records of 368 newly diagnosed patients with GBM and identified 47 patients with multifocal tumors.  Tumor progression was defined as increased enhancement on the 2-to 3-month postradiation magnetic resonance imaging scan vs the immediate postoperative scan, together with clinical decline.  Factors leading to the worst median survival duration were age (>65 years), partial resection or biopsy, and low KPS (≤70) within the multifocal group.  The median survival duration of older patients with multifocal disease (age > 65 years) was 4 months vs 12 months in younger patients (P = 0.0007).  Patients with multifocal disease who underwent biopsy or partial resection had a median survival time of 5 months vs the 14-month median survival time seen in patients who underwent gross total or near-gross total resection (P = 0.04).  Patients with multifocal disease with low KPS (<70) had a median survival duration of 3 months vs patients with high KPS (>70) who survived for 9 months (P = 0.04).  Survival rates at 2 years were 4.3% for patients with multifocal disease and 29.0% for the unifocal cohort.  Additionally, newly diagnosed patients with multifocal disease had an almost 2-fold increase in the hazard of death vs patients with solitary GBM (hazard ratio, 1.8; 95% CI, 1.1 -3.1; P = 0.02).
 There were no significant differences in expression profile of any of the molecular markers between the multifocal and solitary GBM groups. Quercetin has been studied extensively in variety of tumor types over decades. For a while it has been used in the form of IV in phase I and II trials with good safety and efficacy profile in cancer and other conditions including cardiovascular disease. Recently it has become a focus of interest, in treatment of Glioblastoma along with different forms of radiation and chemotherapy. Mechanisms of action in Glioblastoma have been identified both as independent as well as synergistic. Targets include HSP27 and COX2, a dual inhibition found in both in vitro and in vivo model [3] - [18] .
Quercetin also has been studied by our scientific collaboration with M D An- Gamma Knife through leading edge technique showed improved outcome in a large subset of patients with Glioblastoma, due to its antimigratory effect [19] .
The rationale of combination therapy relies on the fact that theoretically, the combinational therapy enhances the inhibition on cellular migration and the application of gamma knife could increase the penetration of IV Quercetin in the blood brain barrier. The limiting factor is the bioavailability and the requirement for frequent treatments.
Methods and Materials
Quercretin was compounded under sterile conditions at FDA approved facility, 
Discussion
Despite the significant recent efforts in research and drug development aimed at treatment of advanced Glioblastoma, yet the prognosis of the disease is grave. 
